Neue psychoaktive Substanzen gewinnen zunehmend an Bedeutung im Bereich der öffentlichen Gesundheit und könnten neue therapeutische Ansätze für psychiatrische und kognitive Störungen ermöglichen. MDMA wird derzeit in Phase-3-Studien als Ergänzung zur Psychotherapie zur Behandlung von PTBS untersucht. Nach zwei Phase-3-Studien forderte die FDA in einem Complete Response Letter weitere...
Background The COVID-19 pandemic has resulted in a significant increase in mental health issues, including depression, anxiety, post-traumatic stress disorder and sleep disturbances, particularly among recently hospitalised patients. Non-pharmacological interventions such as Yoga Nidra and Music Therapy offer cost-effective and accessible alternatives for improving psychological well-being and...
Objetivo: Avaliar a eficácia e a segurança comparativas da psilocibina e do MDMA (3,4-metilenodioximetanfetamina) no tratamento de pacientes com transtorno de estresse pós-traumático (TEPT) e depressão resistente ao tratamento (DRT), com base na evidência disponível de ensaios clínicos randomizados e estudos controlados. Métodos: Revisão sistemática conduzida segundo as diretrizes PRISMA 2020....
INTRODUCTION: Ibogaine is a naturally occurring indole alkaloid with suggested therapeutic potential across substance use disorders, trauma-related conditions, mood disorders, and suicidality. However, its clinical translation has been hindered by safety concerns, regulatory barriers, and uncertainty regarding its complex pharmacology. Recent interest has surged in developing ibogaine analogs...
Predictive processing (PP) accounts often characterize mental illness as maladaptive and epistemically distorting due to mismatches between brain-generated top-down models and bottom-up sensory inputs, with this review identifying exceptions. First, hypervigilance in trauma survivors with PTSD or depression may sustain desirable gaps between anticipated problems and actual harms that would...
Introduction: Insomnia and obstructive sleep apnea (OSA) are the most prevalent sleep disorders in military personnel. People with both sleep problems (co-morbid insomnia and sleep apnea [COMISA]) experience higher rates of medical and psychiatric comorbidities. Few studies have examined the comorbidity of nightmares among those with insomnia, OSA, or COMISA. This secondary data analysis of...
Objective This study evaluated whether intramuscular (IM) ketamine is non‐inferior to intranasal (IN) esketamine for treatment‐resistant depression (TRD) and assessed differences in safety and healthcare costs. Methods In a retrospective, observational sequential cohort at the VA San Diego, 179 Veterans with TRD received eight treatments of either IN esketamine ( n = 89) or IM ketamine ( n =...
ABSTRACT Posttraumatic stress disorder (PTSD) is a mental health condition that can develop following exposure to a traumatic event, often with persistent anxiety and depressive symptoms. Recent research suggests the microbiome-gut-brain axis may play an important role in the etiology and pathophysiology of PTSD. At the same time, retreats incorporating psychedelic-assisted therapies have...
Abstract Aim Ketamine is increasingly used for treatment-resistant depression, bipolar disorder, PTSD, chronic pain, and other psychiatric conditions[8,9]. As more adults receive serial ketamine infusions or intranasal esketamine, perioperative considerations with ongoing NMDA-receptor modulation. However, perioperative guidance remains limited, creating uncertainty around anesthetic dosing,...
Psychedelic and substance-assisted therapies are attracting renewed scientific, clinical, and public interest as potential interventions for mental health disorders, particularly treatment-resistant depression, post-traumatic stress disorder, and substance use disorders. However, as the field moves from early efficacy trials toward clinical implementation, major questions remain regarding...